NCT06866938View on ClinicalTrials.gov

Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2030

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

[177Lu]Lu-PSMA-617 (Pluvicto, Novartis)

"Patients will be treated with intravenous \[177Lu\]Lu-PSMA-617 (Pluvicto, Novartis).~One injection every 6 weeks at the dose of 7.4 GBq (±10%)"

Trial Locations (13)

14076

NOT_YET_RECRUITING

Oncologie Médicale, Centre François Baclesse, Caen

29200

NOT_YET_RECRUITING

Oncologie Médicale, CHU Brest-Hôpital Morvan, Brest

33000

NOT_YET_RECRUITING

Médecine Nucléaire, Institut Bergonié, Bordeaux

38043

NOT_YET_RECRUITING

Médecine Nucléaire, Centre Hospitalier de Grenoble Alpes, Grenoble

42270

NOT_YET_RECRUITING

Oncologie Médicale, CHU Saint Etienne, Saint-Priest-en-Jarez

44000

NOT_YET_RECRUITING

Médecine Nucléaire, CHU de Nantes Hôtel-Dieu, Nantes

63011

NOT_YET_RECRUITING

Oncologie Médicale, Centre Jean Perrin, Clermont-Ferrand

67200

NOT_YET_RECRUITING

Médecine Nucléaire, Institut de Cancérologie de Strasbourg, Strasbourg

69310

RECRUITING

Oncologie Médicale, Centre Hospitalier Lyon Sud, HCL, Pierre-Bénite

69373

NOT_YET_RECRUITING

Médecine Nucléaire, Centre Léon Berard, Lyon

76038

NOT_YET_RECRUITING

Oncologie Médicale, Centre Henri Becqueret, Rouen

94800

NOT_YET_RECRUITING

Médecine Nucléaire, Institut Gustave Roussy, Villejuif

06189

NOT_YET_RECRUITING

Oncologie Médicale, Centre Antoine Lacassagne, Nice

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER